Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07428473 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Study acronym: STX-1150-01
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 2 to 3 Start date changed from estimate of Jun 2026 to Jun 30, 2026 · Eligibility criteria expanded, about 8 words Show 2 more changesShow less
    • Start date changed from estimate of Jun 2026 to Jun 30, 2026
    • Eligibility criteria expanded, about 8 words
  2. Recruitment opened Study sites: 1 to 2 · Start date: Jun 1, 2026 to Jun 2026v4 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date: Jun 1, 2026 to Jun 2026
  3. Eligibility criteria shortened, about 499 words Secondary endpoints revised (7) · Primary endpoints revised (3) · Study description shortened, about 161 wordsv3 Show 3 more changesShow less
    • Secondary endpoints revised (7)
    • Primary endpoints revised (3)
    • Study description shortened, about 161 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study title shortened, about 9 wordsv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene. STX-1150 comprises an mRNA and guide RNA (gRNA) delivered via lipid nanoparticles (LNP) for intravenous infusion. The mRNA produces a protein that switches off the PCSK9 gene expression without altering the DNA sequence. This process leverages natural mechanisms that regulate gene activity. The study will enroll up to 64 participants with elevated LDL-C across sites in Australia and New Zealand. The follow-up period will be up to 1- year post-treatment.
Trial Details
NCT Number NCT07428473
Lead Sponsor Monash University
Collaborators: Scribe Therapeutics Inc.
Conditions Elevated LDL-C and High Cholesterol
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov